Terms: = Leukemia AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Diagnosis
563 results:
1. Genetic mutations and immune microenvironment: unveiling the connection to AML prognosis.
Hu Z; Yang Y; Li J; Hu Z
Hematology; 2024 Dec; 29(1):2346965. PubMed ID: 38687637
[TBL] [Abstract] [Full Text] [Related]
2. Cytogenetic abnormalities and tp53 and RAS gene profiles of childhood acute lymphoblastic leukemia in Morocco.
Skhoun H; El Fessikh M; El Alaoui Al Abdallaoui M; Khattab M; Belkhayat A; Chebihi ZT; Hassani A; Abilkassem R; Agadr A; Dakka N; El Baghdadi J
Arch Pediatr; 2024 May; 31(4):238-244. PubMed ID: 38679547
[TBL] [Abstract] [Full Text] [Related]
3. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape.
Karel D; Valburg C; Woddor N; Nava VE; Aggarwal A
Curr Oncol; 2024 Apr; 31(4):1971-1993. PubMed ID: 38668051
[TBL] [Abstract] [Full Text] [Related]
4. Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma, Version 2.2024.
Wierda WG; Brown J; Abramson JS; Awan F; Bilgrami SF; Bociek G; Brander D; Cortese M; Cripe L; Davis RS; Eradat H; Fakhri B; Fletcher CD; Gaballa S; Hamid MS; Hill B; Kaesberg P; Kahl B; Kamdar M; Kipps TJ; Ma S; Mosse C; Nakhoda S; Parikh S; Schorr A; Schuster S; Seshadri M; Siddiqi T; Stephens DM; Thompson M; Ujjani C; Valdez R; Wagner-Johnston N; Woyach JA; Sundar H; Dwyer M
J Natl Compr Canc Netw; 2024 Apr; 22(3):175-204. PubMed ID: 38626800
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real-world evidence in our current therapeutic era.
Iat A; Loschi M; Benachour S; Calleja A; Chiche E; Sudaka I; Aquaronne D; Ferrero C; Fenwarth L; Marceau A; Fournier E; Dadone-Montaudie B; Cluzeau T
Cancer Med; 2024 Mar; 13(6):e7103. PubMed ID: 38506267
[TBL] [Abstract] [Full Text] [Related]
6. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
Troussard X; Maître E; Paillassa J
Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
[TBL] [Abstract] [Full Text] [Related]
7. Gene expression profiling on CML patients with Philadelphia translocation.
Alkhatabi H; Aldahlawi S; Hazzazi MS; Alsolami R; Elaimi A; Almashjary MN; Alserihi R; Alkhatabi HA; Alquthami ME; Daous YM; Bahashwan S; Yasin EB; Barefah A; Alsayes F
Eur Rev Med Pharmacol Sci; 2024 Feb; 28(4):1340-1355. PubMed ID: 38436167
[TBL] [Abstract] [Full Text] [Related]
8. Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study.
Gerhardt A; Dörfel S; Schulz H; Schlag R; Vornholz L; Nejad-Asgari S; Welslau M
Eur J Haematol; 2024 Jun; 112(6):927-937. PubMed ID: 38342972
[TBL] [Abstract] [Full Text] [Related]
9. WT1 and tp53 as valuable diagnostic biomarkers for relapse after hematopoietic stem cell transplantation in acute myeloid leukemia.
Asghari-Ghomi A; Fallahian F; Garavand J; Mohammadi MH
Mol Biol Rep; 2024 Feb; 51(1):244. PubMed ID: 38300383
[TBL] [Abstract] [Full Text] [Related]
10. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
11. [Suspicion of constitutional abnormality at diagnosis of childhood leukemia: Update of the leukemia committee of the French Society of Childhood Cancers].
Strullu M; Cousin E; de Montgolfier S; Fenwarth L; Gachard N; Arnoux I; Duployez N; Girard S; Guilmatre A; Lafage M; Loosveld M; Petit A; Perrin L; Vial Y; Saultier P
Bull Cancer; 2024 Mar; 111(3):291-309. PubMed ID: 38267311
[TBL] [Abstract] [Full Text] [Related]
12. An effective treatment and suspicious adverse reaction to Ibrutinib in a patient diagnosed with splenic B-cell lymphoma/leukaemia with prominent nucleoli: A first case report.
Shen MX; Li FL; Luo XS; Wang ZM
Medicine (Baltimore); 2023 Dec; 102(52):e36022. PubMed ID: 38206706
[TBL] [Abstract] [Full Text] [Related]
13. IMMUNOPHENOTYPE OF LEUKEMIC CELLS IN CHRONIC LYMPHOCYTIC leukemia PATIENTS WITH NOTCH1 AND SF3B1 GENE MUTATIONS.
Golyarnik N; Абраменко І; Movchan G; Martina Z; Dyagil I; Chumak A; Bazyka D
Exp Oncol; 2023 Dec; 45(3):322-327. PubMed ID: 38186023
[TBL] [Abstract] [Full Text] [Related]
14. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis.
Ren W; Wan H; Own SA; Berglund M; Wang X; Yang M; Li X; Liu D; Ye X; Sonnevi K; Enblad G; Amini RM; Sander B; Wu K; Zhang H; Wahlin BE; Smedby KE; Pan-Hammarström Q
Leukemia; 2024 Mar; 38(3):610-620. PubMed ID: 38158444
[TBL] [Abstract] [Full Text] [Related]
15. Acute Lymphoblastic leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
Saygin C; Zhang P; Stauber J; Aldoss I; Sperling AS; Weeks LD; Luskin MR; Knepper TC; Wanjari P; Wang P; Lager AM; Fitzpatrick C; Segal JP; Gharghabi M; Gurbuxani S; Venkataraman G; Cheng JX; Eisfelder BJ; Bohorquez O; Patel AA; Umesh Nagalakshmi S; Jayaram S; Odenike OM; Larson RA; Godley LA; Arber DA; Gibson CJ; Munshi NC; Marcucci G; Ebert BL; Greally JM; Steidl U; Lapalombella R; Shah BD; Stock W
Blood Cancer Discov; 2024 May; 5(3):164-179. PubMed ID: 38150184
[TBL] [Abstract] [Full Text] [Related]
16. tp53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Tefferi A; Fleti F; Chan O; Al Ali NH; Al-Kali A; Begna KH; Foran JM; Badar T; Khera N; Shah M; Hiwase D; Padron E; Sallman DA; Pardanani A; Arber DA; Orazi A; Reichard KK; He R; Ketterling RP; Gangat N; Komrokji R
Br J Haematol; 2024 Apr; 204(4):1243-1248. PubMed ID: 38083865
[TBL] [Abstract] [Full Text] [Related]
17. [Comprehensive diagnosis of Mantle Cell Lymphoma].
Yang H; Guo R; Shi Y; Wang R; Qiao C; Wu YJ; Fan L; Xu W; Li JY; Qiu HR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1720-1725. PubMed ID: 38071051
[TBL] [Abstract] [Full Text] [Related]
18. How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome.
Xian RR
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):51-58. PubMed ID: 38066895
[TBL] [Abstract] [Full Text] [Related]
19. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
Zhang L; Dong H
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
[TBL] [Abstract] [Full Text] [Related]
20. Cytogenetics in the management of mature T-cell and NK-cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Gaillard JB; Chapiro E; Daudignon A; Nadal N; Penther D; Chauzeix J; Nguyen-Khac F; Veronese L; Lefebvre C
Curr Res Transl Med; 2023; 71(4):103428. PubMed ID: 38016421
[TBL] [Abstract] [Full Text] [Related]
[Next]
